Type 2 diabetes mellitus is assotiated with obesity and multiple cardiometabolic risk factors. Improvement in glycemia is often associated with weight gain. Oral antidiabetic agents that can achieve HbA1c reductions plus weight loss and imorovemrnts in aterogenic dyslipidemia. Rimonabant, a selective cannabinoid type 1 CB1 blocker, regulates centrally and peripherally the endigenous overactivity of the endocannabinoid system, promoting reductions in body weight, waist cimcumference and atrogenic dyslipidemia.